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Purpose: We performed this analysis to distinguish the differences in two subtypes of lung 
invasive mucinous adenocarcinoma (IMA) with different kinds of morphological performances, 
in clinicopathological and molecular features, as well as prognosis.
Methods: On the basis of morphological performance, we divided lung IMAs into two 
subgroups, mucus-in-cell adenocarcinoma (MICA) and mucus-out-of-cell adenocarcinoma 
(MOCA). We investigated differences in clinicopathological characteristics, recurrence-free 
survival (RFS), overall survival (OS), and a spectrum of well-identified driver-gene mutations, 
including EGFR, KRAS, HER2, BRAF, ALK, ROS1, and RET, between the two subgroups.
Results: Of 1,699 lung adenocarcinomas, 148 were identified as IMAs (97 MICAs and 
51 MOCAs). The MICA patient group had significantly better RFS than did the MOCA group 
(39.4 months versus 33.0 months, respectively, log rank P=0.020) and significantly better OS 
(54.2 months versus 45.1 months, log rank P=0.034). There were no differences in RFS and 
OS between those with IMAs and those with mucus-negative adenocarcinomas. The frequency 
of the EGFR gene mutation was significantly higher in MOCAs than in MICAs (P,0.001). In 
contrast, the KRAS gene had a significantly higher mutational frequency in MICAs (P=0.01). 
MOCAs also had a significantly higher incidence of lymph-node metastasis (P,0.05).
Conclusion: To our knowledge, this study represents the first comparison of clinical features, 
molecular alterations, and prognosis in morphological subgroups of lung IMAs. Clinical and 
pathological features in conjunction with molecular data indicate that IMA should be divided 
into different subgroups.
Keywords: lung, invasive mucinous adenocarcinoma, prognosis, driver mutations
Introduction
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death 
worldwide.1 The most common pathological subtype of diagnosed NSCLC is adeno-
carcinoma, which has an increasing prevalence. A new classification for lung adeno-
carcinoma was proposed by an international multidisciplinary expert panel from 
International Association for the Study of Lung Cancer/American Thoracic Society/
European Respiratory Society (IASLC/ATS/ERS) in 2011,2 while the definition of 
mucinous bronchioloalveolar carcinoma is no longer used. Invasive mucinous adeno-
carcinoma (IMA) was recognized as a separate subtype of lung adenocarcinoma, which 
was supposed to contain components of columnar or goblet cells with abundant intra-
cellular or extracellular mucus admixed with invasive adenocarcinoma patterns with OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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stromal invasion. Compared with other lung adenocarcinoma 
subtypes, IMA has different immunohistochemical and 
molecular features, as well as a different prognosis.3–5
Mucinous adenocarcinoma occurs in various organs and 
has two main kinds of histological appearance. In one, the 
tumor is composed of columnar or goblet cells with abundant 
intracellular mucus accumulation; in the other, the tumor 
has abundant extracellular mucus admixed with invasive 
adenocarcinoma patterns with stromal invasion. IMAs occur-
ring in lung also share the above two kinds of histological 
appearance. We performed this retrospective study on sur-
gically resected lung IMAs, with the aim to distinguish the 
differences in clinicopathological feature, molecular features, 
and prognosis between IMAs subgroups with these two kinds 
of morphological performance.
Materials and methods
Patients and specimens
From October 2007 to April 2013, patients with newly 
diagnosed primary lung cancer were consecutively enrolled. 
Inclusion criteria for this study included: 1) patients under-
went complete resection of the primary lesion; 2) pathological 
diagnosis of adenocarcinoma was reconfirmed by two pathol-
ogists (L Shen and Y Li); and 3) samples had a minimum of 
50% tumor cells and sufficient corresponding normal tissue 
for mutational analysis. Patients who received any neoadju-
vant chemotherapy or radiotherapy were excluded. Written 
informed consent was acquired from all the enrolled patients. 
This study was approved by our institutional review board.
Clinical and pathological characteristics
Clinicopathological data were collected for analyses of the 
association with IMA subtypes. Sex, smoking history, age at 
diagnosis, pathological cancer stage, histological type, and 
tumor differentiation were included. If a diagnosis of lung 
adenocarcinoma was made, histological subtypes according 
to the new IASLC/ATS/ERS multidisciplinary classification 
were collected.2 The abbreviation “MICA” was used to rep-
resent mucus-in-cell adenocarcinoma, while “MOCA” was 
used to define mucus-out-of-cell adenocarcinoma (Figure 1A, 
MICA; Figure 1B, MOCA). Tumors in which .50% of cells 
contained abundant intracytoplasmic mucus were considered 
to be MICA, whereas tumors with few cells having intra-
cytoplasmic mucus but with abundant extracellular mucus 
admixed with invasive adenocarcinoma patterns were consid-
ered to be MOCA. Lung adenocarcinoma without a mucinous 
component was defined as “mucus-negative”. Patients were 
interviewed every 3 months after the date of diagnosis, either 
in the clinic or by telephone, about disease recurrence and 
survival information. Recurrence-free survival (RFS) was 
calculated from the date of diagnosis to the date of recurrence 
or last-time follow-up. Overall survival (OS) was defined as 
the time elapsed between date of diagnosis to date of cancer-
related death or last-time follow-up.
Mutation and gene-fusion analysis
After the surgery, tissue samples were divided into two 
parts. One part was fixed using formalin and embedded 
with paraffin to make a pathological section; the other part 
was snap-frozen in liquid nitrogen at the time of resection 
and stored in liquid nitrogen. RNA and DNA were extracted 
from tumors, and distant histological normal lung after frozen 
specimens were dissected into TRIZOL (Life Technologies, 
CA, USA). Total RNA samples were reverse transcribed into 
complementary DNA.
EGFR (exons 18–21), KRAS (exons 2–3), HER2 (exons 
18–21), BRAF (exons 11–15), PIK3CA (exons 9 and 20) 
were amplified by polymerase chain reaction (PCR) using 
complementary DNA. Amplified products were assessed 
using the Sanger direct-sequencing method6 in forward and 
reverse directions to detect mutations. All mutations were 
verified by analysis of an independent PCR isolate.7 A com-
bined strategy of quantitative real-time PCR (qRT-PCR) 
and reverse-transcriptase PCR (RT-PCR) was performed to 
assess ALK, ROS1, and RET fusion, with validation using 
fluorescent in situ hybridization.8
Statistical analyses
We adopted Pearson χ2 test or Fisher’s exact test to assess 
the correlations between clinicopathological variables 
and IMA subtypes. Survival curves were made using the 
Kaplan–Meier method. Recurrence-free survival and overall 
survival were compared using log–rank test. Cox regression 
was performed to assess the effect of clinicopathological 
characteristics, including IMA subtypes, upon survival. 
Figure 1 Different morphological appearances of lung invasive adenocarcinoma.
Notes:  (A)  Mucus-in-cell  adenocarcinoma  (.50%  of  tumor  cells  with 
abundant  intracytoplasmic  mucus; 1 0*10  magnification).  (B)  Mucus-out-of-cell 
adenocarcinoma  (tumor  cells  with  abundant  extracellular  mucus  admixed  with 
invasive adenocarcinoma patterns; 10×10 magnification).OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2129
Subgroups of lung invasive mucinous adenocarcinoma
The statistical analyses were performed using SPSS 16.0 for 
Windows (SPSS Inc., Chicago, IL, USA). All the tests were 
two-tailed, and statistical significance was set as P,0.05.
Results
Of 1,699 lung adenocarcinomas, 148 tumors turned out to 
be IMAs; of these, 97 were MICAs and 51 were MOCAs. 
There were 73 women and 75 men in this group, ranging in 
age at diagnosis from 23–84 years of age (median, 60 years). 
Nonsmokers comprised 67.6% (100 of 148) of patients. The 
number of patients with pathological stage I, II, and III cancer 
was 90, 22, and 36, respectively (Table 1).
Through further comparison of the clinicopathological 
features between MICA and MOCA, we found that MOCAs 
had a significantly higher incidence of lymph-node metastasis 
(26.8% versus 43.1%, P,0.05). There was no significant dif-
ference between the two categories in sex or age at diagnosis, 
nor in smoking history. The morphological performance 
of mucus was not significantly correlated with tumor size, 
pathological stage, or lymphovascular invasion (Table 1).
In the 148 IMA cases, we detected 45 (30.4%) EGFR 
mutations, 25 (16.9%) KRAS mutations, nine (6.1%) HER2 
mutations, and two BRAF (1.3%) mutations. We also found 
20 (13.5%) ALK fusions, six (4.1%) RET fusions, and three 
(2.0%) ROS1 fusions. All of these molecular alterations were 
mutually exclusive. Further, 27 (18.2%) MICA and 11 (7.4%) 
MOCA harbored none of the above molecular changes. The 
frequency of EGFR gene mutation was significantly higher in 
MOCAs than in MICAs (49.1% versus 20.6%, P,0.001). In 
contrast, the KRAS gene had a significantly higher mutational 
frequency in MICAs (22.7% versus 5.9%, P=0.01). The fre-
quency of other well-identified driver-gene mutations did not 
significantly vary with different morphological performance 
of mucus (Table 1).
We further compared the clinical outcomes between 79 
IMA and 439 consecutive mucus-negative lung adenocar-
cinomas, all of which were diagnosed from October 2007 
to October 2011. We analyzed RFS and OS data from these 
two subgroups of patients. The median follow-up phase 
for the IMA group was 43.6 months and for the mucus-
negative group was 48.5 months. The RFS and OS were not 
significantly different between IMA and mucus-negative 
lung adenocarcinoma groups (RFS: 37.2 months versus 38.8 
months, respectively, log-rank P=0.524; OS: 49.5 months 
versus 63.5 months, respectively, log-rank P=0.650; Figure 
2A and B). When IMAs were divided into MICA and MOCA 
subgroups and compared with the mucus-negative group, 
survival data showed a trend of difference between the three 
groups, but the results failed to reach statistical significance 
(RFS: MICA versus mucus-negative, log-rank P=0.189; 
RFS: MOCA versus mucus-negative, log-rank P=0.648; 
OS: MICA versus mucus-negative, log-rank P=0.312; OS: 
MOCA versus mucus-negative, log-rank P=0.106; Figure 
2C and D).
We then compared clinical outcomes between 38 MICAs 
and 41 MOCAs. Median follow-up time for the MICA group 
was 39.6 months and for the MOCA group was 41.5 months. 
Compared with the MICA group, the MOCA group had 
significantly worse RFS (39.4 months versus 33.0 months, 
respectively, log-rank P=0.020) and OS (54.2 months 
versus 45.1 months, respectively, log-rank P=0.034) 
(Figure 2C and D). Smoking history was also correlated 
with worse RFS (31.4 months versus 39.9 months, respec-
tively, log-rank P=0.021) in IMAs, but no significant differ-
ences were found in OS (47.9 months versus 50.6 months, 
respectively, log-rank P=0.47). Lymph node metastasis also 
Table 1 Clinicopathological and molecular features of mucus-in-
cell adenocarcinoma and mucus-out-of-cell adenocarcinoma
Variables MICA (n=97) MOCA (n=51) P-value
Sex
  Male 45 30 0.151
  Female 52 21
Age, years
  $60 48 25 0.957
  ,59 49 26
Smoking history
  Smoker 27 21 0.099
  Never 70 30
Tumor size
  #3 cm 62 28 0.286
  .3 cm 35 23
Cancer stage
  I/II 76 36 0.296
  III 21 15
Lymphovascular invasion
  + 17 10 0.099
  - 80 41
Lymph node metastasis
  N0 71 29 0.044
  N1–N3 26 22
Mutational status
  EGFR mutation 20 25 ,0.001
  KRAS mutation 22 3 0.01
  HER2 mutation 5 4 0.515
  BRAF mutation 2 0 0.302
  ALK fusion 16 4 0.206
  ROS1 fusion 2 1 0.999
  RET fusion 3 3 0.415
  Pan-negative 27 11 0.407
Abbreviations: MICA, mucus-in-cell adenocarcinoma; MOCA, mucus-out-of-cell 
adenocarcinoma.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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predict worse RFS (31.6 months versus 41.0 months, log 
rank P=0.007) and OS (44.3 months versus 53.0 months, 
log rank P=0.018) in 79 IMAs. Age at diagnosis, sex, lym-
phovascular invasion, and driver-gene mutational status had 
no significant correlations with RFS and OS. Multivariate 
analysis of survival significance was also performed, with 
age at diagnosis, sex, smoking history, mucus pattern, lym-
phovascular invasion, lymph node metastasis, and EGFR 
gene mutational status included. Lymph-node metastasis 
was the only independent factor of RFS (odd ratio =3.24, 
95% confidence interval =1.32–4.76, P,0.01), but had no 
significance for predicting OS.
Discussion
Since the appearance of the IASLC/ATS/ERS classification 
of lung adenocarcinoma in 2011, many studies have focused 
on the influence of pathological subtype on prognosis and 
molecular change.9–11 IMAs, which account for 2%–10% of 
lung adenocarcinoma cases in East Asia, Europe, and the 
United States,11–13 were considered to be more malignant 
than other common subtypes of lung adenocarcinoma, such 
as lepidic and acinar subtypes.14 To our knowledge, this 
is the first study to focus on the differences in prognosis 
and molecular alterations in IMA subgroups with different 
morphological features. Therefore, we performed this study 
to investigate if it is reasonable to divide invasive mucinous 
lung adenocarcinoma into separate parts.
Some previous studies demonstrated that IMAs cor-
related with worse prognosis.4,15 However, in some recent 
studies, IMA subtype failed to reach statistical significance 
as a worse prognosis predictor.16 Considering this discrep-
ancy on the predictive value of IMA subtype on prognosis, 
we performed survival analysis between IMA patients and 
mucus-negative patients. Our results indicated that the IMA 
patients did not have a worse prognosis than mucus-negative 
patients do. Dividing IMAs into two subgroups by different 
morphological performance and comparing all groups, we 
found that patients with MICA showed a potential trend of 
better prognosis than did mucus-negative patients, while 
MOCAs seemed to have the worst prognosis of all three 
subgroups. Our results indicated that IMA subtype alone may 
not be an adequate predictor for worse prognosis. Different 
morphological performances may have potential predictive 
value on clinical outcome.
A B
C D
1.0
0.8
0.6
0.4
R
e
c
u
r
r
e
n
c
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
0.2
0.0
Months
IMAs
IMAs censored
Mucus-negative
Mucus-negative censored
1.0
0.8
0.6
0.4
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
0.2
0.0
Months
IMAs
IMAs censored
Mucus-negative
Mucus-negative censored
1.0
0.8
0.6
0.4
R
e
c
u
r
r
e
n
c
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
0.2
0.0
02 04 0
Months
60 80
MICAs
Mucus-negative
Mucus-negative censored
MOCAs
MICAs censored
MOCAs censored
MICAs
Mucus-negative
Mucus-negative censored
MOCAs
MICAs censored
MOCAs censored
1.0
0.8
0.6
0.4
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
0.2
0.0
02 04 0
Months
60 80 100
02 04 06 08 0 02 04 06 0 80 100
Figure 2 Recurrence-free and overall survival.
Notes: (A) Recurrence-free survival of IMAs or mucus-negative adenocarcinomas. (B) Overall survival of IMAs or mucus-negative adenocarcinomas. (C) Recurrence-free 
survival of MICAs, MOCAs, or mucus-negative adenocarcinomas. (D) Overall survival of MICAs, MOCAs, or mucus-negative adenocarcinomas.
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We also observed distinct prognoses between IMAs with 
different morphological performance. Patients with MICA 
had a better RFS and OS than did their counterparts with 
MOCA. Lymph-node metastasis also occurred more fre-
quently in patients with MOCA. To our knowledge, no simi-
lar study has revealed different clinical outcomes between 
invasive mucinous lung adenocarcinoma subgroups with 
different mucus distributions. Mucinous adenocarcinomas 
in other organs are also associated with lymph-node metas-
tasis and worse prognosis,17–20 and mucus is considered to 
play a critical role in the development of cancer.21 Thus, we 
suspect that the common phenomenon is related to the same 
mucinous component in different cancers. When the mucus 
is out of the cell, the tumor may have aggressive biological 
behavior. However, further study is needed to form a more 
reliable conclusion.
Lung IMA was reported to be associated with higher fre-
quency of KRAS mutation and resistance to EGFR tyrosine 
kinase inhibitor.12,22,23 In our series, the frequency of EGFR 
and KRAS mutation was 30.4% and 16.9%, respectively. Also, 
a higher prevalence of ALK fusion was observed in IMAs than 
in unselected lung adenocarcinoma.24 We further analyzed 
the association between morphological feature and molecular 
alteration, finding that the frequency of EGFR mutation was 
remarkably higher in MOCAs than in MICAs and that KRAS 
mutation significantly prevailed in MICAs. These findings 
suggest that there is a distinct difference in molecular change 
in these two subgroups of IMA, and that MICAs and MOCAs 
are two different kinds of adenocarcinoma. Therefore, more 
accurate distinction is required to be made in IMAs.
The weakness of our work was that this was a retrospec-
tive study. The clinical outcomes had limited significance, 
because some of these patients had different postoperative 
treatments. Meanwhile, a sample size of 148 patients was 
too small to prove the differences between IMA subgroups 
with different morphological features. This issue should be 
confirmed by further research with larger samples.
Conclusion
We found various subtypes of lung IMAs. There are dis-
tinct morphological performances, driver-gene mutation 
distributions, and clinical outcomes in the two subgroups of 
patients. A more precise definition of IMA should be taken 
into consideration in the future.
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